Skip to main content
. 2024 May 27;9:128. doi: 10.1038/s41392-024-01828-x

Table 1.

Expression and clinical features of Notch receptor or ligand in cancers

Category Cancer type Notch receptor/ligand Expression (tumor vs. normal) Clinical feature Prognosis Ref.
Digestive system CRC Notch1 Upregulated Lymph node metastasis, tumor stage, depth of infiltration, histological differentiation Poor 58
CRC Notch2 Downregulated OS Favorable 59
CRC Notch3 Upregulated Tumor differentiation status, tumor recurrence, distant relapse-free survival Poor 60
CRC Notch4 Downregulated Tumor differentiation, invasion, node metastasis, disease-free and OS Favorable 61
CRC JAG1 Upregulated OS, relapse-free survival Poor 62
CRC JAG2 Upregulated Clinical stages Poor 63
CRC DLL4 Upregulated OS, perineural invasion, distant metastasis Poor 64
HCC Notch1, Notch4 Upregulated Disease-specific survival Poor 69
HCC Notch2 Upregulated Clinical stages Poor 71
HCC Notch3 Upregulated Tumor size, TNM stage, OS Poor 74
HCC JAG1 Upregulated Differentiation grade Poor 76
HCC JAG2 Upregulated Intrahepatic metastasis, histological grade, TNM stage Poor 78
ESCC Notch1 Upregulated Tumor grade and stage Poor 85
ESCC Notch2 Upregulated OS and PFS Poor 87
ESCC Notch3 N/A Chemotherapy sensitivity Favorable 88
GC Notch1 Upregulated Lymph node metastasis Poor 91
GC Notch3 N/A Immune tolerance Favorable 97
GC JAG1 Downregulated OS Favorable 98
PC Notch3 Upregulated OS Poor 104
PC JAG1 Upregulated OS Poor 106
PC DLL4 N/A Advanced tumor stage, lymph node metastasis Poor 107
CCA Notch1 Upregulated Tumor size, HBsAg positive Poor 123
CCA Notch3 Upregulated N/A Poor 124
CCA JAG1 Upregulated N/A Poor 125
Respiratory system NSCLC Notch1 Upregulated Lymph node metastasis, TNM stages Poor 129
NSCLC Notch4, DLL4 Upregulated Tumor size, lymph node metastasis, distant metastasis, TNM stage Favorable 130
NSCLC JAG1, JAG2, DLL1 Downregulated N/A N/A 131
SCLC DLL3 Upregulated N/A N/A 147
Postoperative SCLC DLL3 Upregulated PFS, chemoresistance Poor 148
Hematological malignancies Adult T-ALL Notch1 Mutation OS, event-free survival Favorable 168
Pediatric T-ALL Notch1 Mutation OS Favorable 169
CLL Notch1 Mutation PFS Poor 179
CLL Notch2 Upregulated Apoptosis characteristic Poor 182
CLL JAG1 Upregulated N/A N/A 184
Urinary system Bladder cancer Notch1–3 Mutation OS Poor 189
Bladder cancer Notch2 Upregulated Adverse disease parameters Poor 191
Bladder cancer Notch3 Upregulated Cancer-specific mortality Poor 193
Bladder cancer JAG2 Upregulated Tumor size, stage Poor 194
PCa Notch1 Upregulated High-risk, metastasis Poor 199
PCa bone metastasis Notch3 Upregulated Bone metastasis Poor 200
PCa DLL3 Upregulated Survival Poor 204
PCa JAG1 Upregulated Metastasis, recurrence Poor 201
RCC Notch1 Downregulated Tumor stage N/A 210
RCC Notch3 Dysregulated Chromophobe RCC, unbroken capsule, Fuhrman grade, lymph node involvement N/A 213
ccRCC Notch Copy number variance OS Favorable 217
ccRCC Notch1 Upregulated Tumor stage, diameter Poor 218
ccRCC JAG1 Upregulated Tumor size, nuclear grade, TNM stage Poor 220
ccRCC DLL4 Upregulated Tumor grade, tumor stage, survival Poor 219
Reproductive system Breast cancer JAG1 and Notch1 Upregulated OS, median survival Poor 226
Breast cancer Notch2 Dysregulated Subgroups, genotypes Poor 231
Breast cancer Notch4 Upregulated Tumor size, lymph node involvement, metastasis stage Poor 227
Breast cancer DLL3 Upregulated Immune cell infiltration Poor 229
Breast cancer DLL4 Upregulated Nodal and distant metastasis Poor 230
Breast cancer DLL4, JAG1 Upregulated Metastasis, tumor stage Poor 228
OC Notch1 Upregulated Pathology stage, OS Poor 176
OC Notch2/3, DLL3 Upregulated Overall, disease-free survival, stages Poor 242
OC Notch3 Upregulated Progression-free/OS Poor 243
OC DLL4 Upregulated Survival Poor 244
CC JAG1/Notch1 Upregulated Invasion, lymph node metastasis, FIGO system Poor 254
CC DLL4 Upregulated Death and recurrence Poor 255
Nervous system Oligodendroglioma Notch1 Mutation Survival Poor 266
Glioma Notch1 Upregulated OS Poor 267
Glioma Notch3 Upregulated Grade, OS Poor 268
Glioma DLL3 Upregulated Prognosis Favorable 269
Neuroblastoma Notch1 Upregulated Advanced tumor stages, MYCN amplification, undifferentiated histology, low CRT expression level Poor 281
Tumors of other systems Melanoma Notch4 Mutation OS Favorable 293
Osteosarcoma Notch3 Upregulated Survival Poor 296
Osteosarcoma JAG1 Upregulated Metastasis, recurrence Poor 297
Osteosarcoma DLL4 Upregulated Enneking stage and metastasis, tumor differentiation Poor 298
Thyroid cancer Notch1 80.5% positive Lymph node metastasis Poor 307
Thyroid cancer DLL4 54% positive Invasion and metastasis Poor 308
Thyroid cancer Notch3 Downregulated Tumor size, distant metastasis, survival Favorable 309
OSCC Notch1 Upregulated T-stage, clinical stage Poor 314
OSCC Notch3 33% positive Tumor size Poor 316
OSCC Notch4 Upregulated Late stage Poor 317
HNSCC Notch1/2/3 Mutation N/A N/A 326
HNSCC Notch1 Upregulated Early stages, non-recurrent disease, better disease-specific, OS Favorable 330

CRC colorectal cancer, HCC hepatocellular carcinoma, ESCC esophageal squamous cell carcinoma, GC gastric cancer, PC pancreatic cancer, CCA cholangiocarcinoma, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, T-ALL T cell acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, PCa prostate cancer, RCC renal cell carcinoma, ccRCC clear cell renal cell carcinoma, OC ovarian cancer, CC cervical cancer, OSCC oral squamous cell carcinoma, HNSCC head and neck squamous cell carcinoma, OS overall survival, PFS progression-free survival, TNM tumor-node-metastasis